<DOC>
	<DOCNO>NCT00251095</DOCNO>
	<brief_summary>The purpose study compare objective response rate patient randomize receive either TOCOSOL ( R ) Paclitaxel Taxol ( R ) ( paclitaxel injection ) administer every week patient metastatic breast cancer . The study hypothesis objective response rate TOCOSOL Paclitaxel give every week non-inferior observed Taxol give every week .</brief_summary>
	<brief_title>Comparison Safety Efficacy TOCOSOL ( R ) Paclitaxel Versus Taxol ( R ) Treatment Metastatic Breast Cancer</brief_title>
	<detailed_description>Female patient first second line metastatic breast cancer randomize receive either weekly TOCOSOL Paclitaxel weekly Taxol ( paclitaxel injection ) . Patients undergo radiographic image disease assess response therapy . The primary endpoint study comparison objective response rate observe patient receive TOCOSOL Paclitaxel , receive Taxol . Time-to-disease progression overall survival also compare . The toxicity two treatment regimen compare .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patients histologic diagnosis breast carcinoma Stage IV ( M1 ) disease Adult ( 18 year age old ) patient Patients treat taxane within past year Patients whose tumor tissue know show expression HER2/neu</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Metastatic Breast Cancer</keyword>
</DOC>